# Dose-Ranging Study in Treatment Naive Type 2 Diabetes Mellitus(T2DM)

> **NCT00500331** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 334 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** GSK189075
- **DRUG:** pioglitazone
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00500331
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01-23
- **Primary completion:** 2008-02-14
- **Final completion:** 2008-02-14
- **Target enrollment:** 334 (ACTUAL)
- **Last updated:** 2017-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00500331

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00500331, "Dose-Ranging Study in Treatment Naive Type 2 Diabetes Mellitus(T2DM)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00500331. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*